{"id":45614,"date":"2026-04-18T08:23:31","date_gmt":"2026-04-18T06:23:31","guid":{"rendered":"https:\/\/semaxpolska.com\/?p=45614"},"modified":"2026-04-10T08:37:03","modified_gmt":"2026-04-10T06:37:03","slug":"ka-vara-peptids-saista-vara-jonus-biokimiskajos-petijumos","status":"publish","type":"post","link":"https:\/\/bioevidencehub.com\/lv\/jak-peptyd-miedziowy-wiaze-jony-miedzi-w-badaniach-biochemicznych\/","title":{"rendered":"K\u0101 vara pept\u012bds biolo\u0123isk\u0101s \u0137\u012bmijas p\u0113t\u012bjumos saista vara jonus?"},"content":{"rendered":"

Vara pept\u012bds saista vara jonus, veidojot stabilu kompleksu, kur\u0101 tas izmanto noteiktus sl\u0101pek\u013ca atomus, lai notur\u0113tu vara jonu sak\u0101rtot\u0101 un kontrol\u0113t\u0101 strukt\u016br\u0101. Bio\u0137\u012bmiskos p\u0113t\u012bjumos \u0161is process notiek attiec\u012bb\u0101 1:1, kas noz\u012bm\u0113, ka viena pept\u012bda molekula saista vienu vara jonu (Cu\u00b2\u207a), veidojot kompleksu, kas paz\u012bstams k\u0101 GHK-Cu.<\/p>\n

Molekul\u0101raj\u0101 l\u012bmen\u012b \u0161\u012b saikne ietver vair\u0101kus savienojuma punktus, ko d\u0113v\u0113 par koordin\u0101cijas viet\u0101m. Vara jons tiek tur\u0113ts ar sl\u0101pek\u013ca atomiem, kas n\u0101k no da\u017e\u0101d\u0101m pept\u012bda da\u013c\u0101m. Tie ietver glic\u012bna amingrupu (vienu no aminosk\u0101b\u0113m), sl\u0101pek\u013ca atomu no pept\u012bdu saiknes starp glic\u012bnu un histid\u012bnu, k\u0101 ar\u012b sl\u0101pek\u013ca atomu no histid\u012bna imidazola gredzena (met\u0101lus sp\u0113j\u012bgas saist\u012bt strukt\u016bras). Ceturto poz\u012bciju parasti ie\u0146em v\u0101ji saist\u012bts ligands, piem\u0113ram, \u016bdens molekula vai cits neliels savienojums. Kop\u0101 \u0161ie elementi veido stabilu \u0123eometrisku strukt\u016bru, ko bie\u017ei raksturo k\u0101 plakani kvadr\u0101tveida, kas notur vara jonu pareizaj\u0101 poz\u012bcij\u0101.<\/p>\n

Laboratoriskie m\u0113r\u012bjumi par\u0101da, ka \u0161\u012b saite ir \u013coti sp\u0113c\u012bga fiziolo\u0123iskai videi tuvos apst\u0101k\u013cos. T\u0101 tiek raksturota ar stabilit\u0101tes konstantiem, kas nor\u0101da, cik cie\u0161i divas molekulas paliek savienotas. \u0160aj\u0101 gad\u012bjum\u0101 v\u0113rt\u012bbas apstiprina, ka var\u0161 cie\u0161i saist\u0101s ar pept\u012bdu un nav br\u012bv\u0101 veid\u0101. \u0160\u012bs strukt\u016bras apstiprin\u0101\u0161anai tiek izmantotas modernas metodes, piem\u0113ram, UV-Vis spektroskopija, cirkul\u0101rais dihroisms un elektronu paramagn\u0113tisk\u0101 rezonanse. \u0160\u012bs metodes \u013cauj prec\u012bzi noteikt vara koordin\u0101cijas veidu un par\u0101d\u012bt, ka tas var atrasties nedaudz at\u0161\u0137ir\u012bgos sai\u0161u st\u0101vok\u013cos atkar\u012bb\u0101 no vides.<\/p>\n

Saist\u012b\u0161an\u0101s process nav piln\u012bgi stingrs. Tas izr\u0101da zin\u0101mu elast\u012bbu un var piel\u0101goties citu molekulu kl\u0101tb\u016btnei. Piem\u0113ram, savienojumi, kas satur imidazolu grupas, vai molekulas, piem\u0113ram, urokan\u012bnsk\u0101be, var mijiedarboties ar kompleksu. Tas var novest pie sare\u017e\u0123\u012bt\u0101ku strukt\u016bru, ko sauc par tr\u012bskomponentu kompleksiem, veido\u0161an\u0101s, kas v\u0113l vair\u0101k stabiliz\u0113 varu, to neatbr\u012bvojot. \u0160\u012b elast\u012bba par\u0101da, ka vara pept\u012bds var dro\u0161i saist\u012bt varu, vienlaikus piel\u0101gojoties da\u017e\u0101diem bio\u0137\u012bmiskiem apst\u0101k\u013ciem.<\/p>\n

\u0160im meh\u0101nismam ir noz\u012bme, jo tas \u013cauj kontrol\u0113t vara uzved\u012bbu organism\u0101. Br\u012bvie vara joni var izrais\u012bt nev\u0113lamas \u0137\u012bmiskas reakcijas, \u012bpa\u0161i t\u0101s, kas noved pie oksidat\u012bv\u0101 stresa. Savuk\u0101rt p\u0113c sasaist\u012b\u0161anas ar vara pept\u012bdu to aktivit\u0101te tiek regul\u0113ta un novirz\u012bta kontrol\u0113t\u0101k\u0101 un biolo\u0123iski lietder\u012bg\u0101k\u0101 veid\u0101.<\/p>\n

P\u0113t\u012bjumu apst\u0101k\u013cos izmantotais vara pept\u012bds ir pieejams pie t\u0101diem pieg\u0101d\u0101t\u0101jiem k\u0101 SemaxPolska. L\u016bdzu, \u0146emiet v\u0113r\u0101, ka vara saist\u012b\u0161an\u0101s \u012bpa\u0161\u012bbas ir nov\u0113rotas kontrol\u0113tos laboratorijas apst\u0101k\u013cos un nav tie\u0161s cilv\u0113ka organism\u0101 notieko\u0161o efektu apstiprin\u0101jums bez turpm\u0101kiem p\u0113t\u012bjumiem.<\/p>\n

K\u0101du lomu vara pept\u012bdam ir vara metabolism\u0101, saska\u0146\u0101 ar p\u0113t\u012bjumiem?<\/strong><\/h2>\n

P\u0113t\u012bjumi liecina, ka vara pept\u012bds darbojas gan k\u0101 vara jonu nes\u0113js, gan k\u0101 to regulators, pal\u012bdzot tos organism\u0101 p\u0101rnest kontrol\u0113t\u0101 un biolo\u0123iski dro\u0161\u0101 veid\u0101. T\u0101 viet\u0101, lai atrastos br\u012bv\u0101 veid\u0101, kas var b\u016bt \u013coti reakt\u012bva un potenci\u0101li kait\u012bga, var\u0161 saist\u0101s ar pept\u012bdu, kas nodro\u0161ina t\u0101 transport\u0113\u0161anu un izmanto\u0161anu biolo\u0123iskaj\u0101s sist\u0113m\u0101s.<\/p>\n

Laboratoriskajos un \u0161\u016bnu p\u0113t\u012bjumos vara pept\u012bds bie\u017ei tiek raksturots k\u0101 vara pieg\u0101des sist\u0113ma. Tas var ievad\u012bt varu \u0161\u016bn\u0101s, vienlaikus kontrol\u0113jot t\u0101 aktivit\u0101ti un ierobe\u017eojot toksicit\u0101ti. Komplekss uztur varu Cu(II) form\u0101, kas ir stabils oksid\u0101cijas st\u0101voklis, un ierobe\u017eo t\u0101 l\u012bdzdal\u012bbu nekontrol\u0113t\u0101s \u0137\u012bmisk\u0101s reakcij\u0101s, kas paz\u012bstamas k\u0101 redoksa reakcijas. \u0160\u012bs reakcijas var rad\u012bt kait\u012bgas molekulas, t\u0101p\u0113c to kontrole pal\u012bdz pasarg\u0101t \u0161\u016bnas no boj\u0101jumiem. Tas \u013cauj vara piedal\u012bties svar\u012bgos procesos, piem\u0113ram, enz\u012bmu aktivit\u0101t\u0113 un \u0161\u016bnu regul\u0101cij\u0101, neradot oksidat\u012bvu stresu.<\/p>\n

Viens no ierosin\u0101tajiem meh\u0101nismiem ir prote\u012bnu, kas paz\u012bstami k\u0101 vara chaperoni, piem\u0113ram, Atox1 un CCS, l\u012bdzdal\u012bba. Tie ir specializ\u0113ti transporta prote\u012bni, kas novirza varu uz noteikt\u0101m viet\u0101m \u0161\u016bn\u0101, tostarp uz kodolu, kur notiek g\u0113nu aktivit\u0101tes regul\u0101cija. Vara pept\u012bds var atbalst\u012bt \u0161o sist\u0113mu, nodro\u0161inot varu form\u0101, kas ir gatava lieto\u0161anai un nodo\u0161anai \u0161iem prote\u012bniem. Tas veido saikni starp vara metabolismu, g\u0113nu regul\u0101ciju un visp\u0101r\u0113jo \u0161\u016bnu signaliz\u0101ciju.<\/p>\n

Turpm\u0101k\u0101 inform\u0101cija par vara pept\u012bdu ir saist\u012bta ar izmai\u0146\u0101m audu aug\u0161anas un atjauno\u0161an\u0101s procesos. P\u0113t\u012bjumi ir par\u0101d\u012bju\u0161i paaugstin\u0101tu t\u0101du faktoru l\u012bmeni k\u0101 VEGF (saist\u012bts ar asinsvadu veido\u0161anos), BDNF (saist\u012bts ar smadze\u0146u darb\u012bbu) un BMP-2 (svar\u012bgs audu att\u012bst\u012bbai) sist\u0113m\u0101s, kur\u0101s ir kl\u0101teso\u0161s vara pept\u012bds. \u0160ie efekti, iesp\u0113jams, ir saist\u012bti ar vara pieejam\u012bbas ietekmi uz sign\u0101lu p\u0101rraides ce\u013ciem, nevis ar tie\u0161u pept\u012bda saist\u012b\u0161anos ar receptoriem.<\/p>\n

Vara pept\u012bds var ar\u012b pal\u012bdz\u0113t uztur\u0113t vara l\u012bdzsvaru organism\u0101, darbojoties k\u0101 buferis. Tas noz\u012bm\u0113, ka tas var saist\u012bt vara p\u0101rpalikumu un ierobe\u017eot t\u0101 kait\u012bgo ietekmi. Eksperiment\u0101los paraugos, piem\u0113ram, p\u0113t\u012bjumos ar zebrziv\u012bm, kas pak\u013cautas augstam vara l\u012bmenim, vara pept\u012bds samazin\u0101ja toksiskos efektus, piem\u0113ram, sirdsdarb\u012bbas trauc\u0113jumus. Tas atbalsta hipot\u0113zi, ka tas var regul\u0113t vara l\u012bmeni un ierobe\u017eot boj\u0101jumus p\u0101rm\u0113r\u012bga vara apst\u0101k\u013cos. J\u0101uzsver, ka sniegtie rezult\u0101ti ir balst\u012bti uz eksperiment\u0101liem paraugiem, un vara pept\u012bda prec\u012bza loma vara metabolism\u0101 cilv\u0113kiem joproj\u0101m tiek p\u0113t\u012bta un nav piln\u012bb\u0101 noteikta.<\/p>\n

K\u0101 vara pept\u012bdi at\u0161\u0137iras no br\u012bvajiem vara joniem biolo\u0123iskaj\u0101s sist\u0113m\u0101s?<\/strong><\/h2>\n

Vara pept\u012bds at\u0161\u0137iras no br\u012bvajiem vara joniem galvenok\u0101rt ar stabilit\u0101ti, reaktivit\u0101ti un biolo\u0123isk\u0101s kontroles pak\u0101pi. Br\u012bvie vara joni ir \u013coti reakt\u012bvi un var piedal\u012bties \u0137\u012bmisk\u0101s reakcij\u0101s, kas izraisa reakt\u012bvo sk\u0101bek\u013ca formu (ROS) veido\u0161anos, kas ir kait\u012bgas \u0161\u016bn\u0101m. Turpretim, kad var\u0161 ir saist\u012bts ar vara pept\u012bdu, tas atrodas stabil\u0101 strukt\u016br\u0101, kas ierobe\u017eo \u0161\u0101das nekontrol\u0113tas reakcijas.<\/p>\n

Br\u012bv\u0101 veid\u0101 var\u0161 var viegli p\u0101riet starp da\u017e\u0101diem oksid\u0101cijas st\u0101vok\u013ciem. Tas \u013cauj inici\u0113t reakcijas, kas izraisa oksidat\u012bvo stresu, kur\u0161 var boj\u0101t prote\u012bnus, lip\u012bdus un DNS. \u0160o risku d\u0113\u013c organisms stingri kontrol\u0113 vara l\u012bmeni, un br\u012bvs var\u0161 ret\u0101k sastopams nesaist\u012bt\u0101 veid\u0101 fiziolo\u0123iskos apst\u0101k\u013cos.<\/p>\n

Vara pept\u012bds maina \u0161o uzved\u012bbu, cie\u0161i saistot varu un ierobe\u017eojot t\u0101s reaktivit\u0101ti. \u0160aj\u0101 form\u0101 potenci\u0101li kait\u012bg\u0101 vara aktivit\u0101te tiek kontrol\u0113ta, vienlaikus saglab\u0101jot t\u0101s l\u012bdzdal\u012bbu labv\u0113l\u012bgos biolo\u0123iskos procesos. Tas noz\u012bm\u0113, ka varu var dro\u0161i transport\u0113t, uzglab\u0101t un izmantot, nekait\u0113jot \u0161\u016bn\u0101m.<\/p>\n

N\u0101kam\u0101 noz\u012bm\u012bg\u0101 at\u0161\u0137ir\u012bba ir vara pieejam\u012bba \u0161\u016bn\u0101m. Br\u012bvie vara joni neiek\u013c\u016bst \u0161\u016bn\u0101s kontrol\u0113ti vai efekt\u012bvi. Savuk\u0101rt vara pept\u012bds veicina vara transportu \u0161\u016bnu iek\u0161ien\u0113. Tas darbojas k\u0101 nes\u0113js, pieg\u0101d\u0101jot varu noteiktiem iek\u0161\u0161\u016bnu ce\u013ciem, kur to var izmantot fermenti vai nodot transporta prote\u012bniem, ko sauc par chaperoniem.<\/p>\n

\u0160\u012bs at\u0161\u0137ir\u012bbas ir nov\u0113rojamas ar\u012b eksperiment\u0101lajos p\u0113t\u012bjumos. Piem\u0113ram, p\u0113t\u012bjumos ar zebrziv\u012bm, kas tika pak\u013cautas augst\u0101m vara koncentr\u0101cij\u0101m, br\u012bvais var\u0161 izrais\u012bja negat\u012bvas sekas, piem\u0113ram, sirds darb\u012bbas trauc\u0113jumus un neregul\u0101ru ritmu. Vara pept\u012bda kl\u0101tb\u016btn\u0113 \u0161\u012bs sekas bija ierobe\u017eotas. Tas par\u0101da, ka vara pept\u012bda komplekss maina vara darb\u012bbas veidu biolo\u0123iskaj\u0101s sist\u0113m\u0101s.<\/p>\n

Turpinot, sprieprodamais vara pept\u012bds var veidot sak\u0101rtot\u0101kas strukt\u016bras ar cit\u0101m molekul\u0101m, ko d\u0113v\u0113 par koordin\u0101cijas kompleksiem. Tie var ietvert mijiedarb\u012bbu ar t\u0101d\u0101m viel\u0101m k\u0101 urokan\u012bnsk\u0101be vai molekul\u0101m, kas satur imidazolu grupas. \u0160\u0101das sak\u0101rtotas mijiedarb\u012bbas v\u0113l vair\u0101k kontrol\u0113 vara aktivit\u0101ti, sal\u012bdzinot ar t\u0101 br\u012bvo jonu formu. J\u0101uzsver, ka aprakst\u012bt\u0101s at\u0161\u0137ir\u012bbas starp br\u012bvo varu un vara pept\u012bdu kompleks\u0101 izriet no eksperiment\u0101liem p\u0113t\u012bjumiem un nav tie\u0161s cilv\u0113ku kl\u012bnisko efektu apstiprin\u0101jums.<\/p>\n

Vai vara pept\u012bds tika p\u0113t\u012bts attiec\u012bb\u0101 uz ceruloplazm\u012bnu un vara transport\u0113\u0161anu?<\/strong><\/h2>\n

Tie\u0161ie p\u0113t\u012bjumi, kas saist\u012btu vara pept\u012bdu ar \u0997\u09be\u09a1\u09bculoplazm\u012bnu, ir ierobe\u017eoti. Tom\u0113r pla\u0161\u0101kas anal\u012bzes par vara transportu organism\u0101 sniedz kontekstu, kas var pal\u012bdz\u0113t lab\u0101k izprast t\u0101s potenci\u0101lo lomu. Caeruloplazm\u012bns ir galvenais asins prote\u012bns, kas atbild\u012bgs par vara transportu, uzturot to stabil\u0101 form\u0101 un nov\u0113r\u0161ot t\u0101 kait\u012bgo ietekmi.<\/p>\n

Vara pept\u012bdam ir zin\u0101mas funkcion\u0101las l\u012bdz\u012bbas ar seruloplazm\u012bnu, jo abi stabili saista varu un ierobe\u017eo t\u0101s reaktivit\u0101ti. Tom\u0113r past\u0101v ac\u012bmredzamas at\u0161\u0137ir\u012bbas. Vara pept\u012bds ir iev\u0113rojami maz\u0101ka molekula, un t\u0101 iedarb\u012bba ir lok\u0101l\u0101ka, kas noz\u012bm\u0113, ka t\u0101, visticam\u0101k, darbojas audu vai \u0161\u016bnu l\u012bmen\u012b, nevis vis\u0101 asinsrites sist\u0113m\u0101, k\u0101 tas ir seruloplazm\u012bna gad\u012bjum\u0101.<\/p>\n

P\u0113t\u012bjumi r\u0101da, ka vara pept\u012bds sp\u0113c\u012bgi saista varu un veido stabilus kompleksus fiziolo\u0123iskos apst\u0101k\u013cos. \u0160ie kompleksi var mijiedarboties ar cit\u0101m molekul\u0101m un piedal\u012bties viet\u0113jos vara apmai\u0146as procesos. Kam\u0113r seruloplazm\u012bns ir atbild\u012bgs par vara transport\u0113\u0161anu asin\u012bs, vara pept\u012bds var atbalst\u012bt prec\u012bz\u0101ku vara pieg\u0101di un sadali noteiktos audos vai \u0161\u016bn\u0101s.<\/p>\n

Ir ar\u012b dati, kas liecina, ka vara pept\u012bds mijiedarbojas ar intracelul\u0101rajiem vara transporta sist\u0113m\u0101m. Vara \u0161aperonu prote\u012bni, piem\u0113ram, Atox1 un CCS, ir atbild\u012bgi par vara nog\u0101d\u0101\u0161anu uz da\u017e\u0101d\u0101m \u0161\u016bnas da\u013c\u0101m, ieskaitot kodolu, kur tiek regul\u0113ta g\u0113nu darb\u012bba. Vara pept\u012bds var kalpot k\u0101 vara avots \u0161\u012bm sist\u0113m\u0101m, atbalstot t\u0101 izmanto\u0161anu \u0161\u016bn\u0101s l\u012bdz\u0101s liel\u0101kiem transporta prote\u012bniem, piem\u0113ram, cearuloplazm\u012bnam.<\/p>\n

Turkl\u0101t vara pept\u012bds var veidot sare\u017e\u0123\u012bt\u0101kas strukt\u016bras ar cit\u0101m molekul\u0101m, ko d\u0113v\u0113 par tr\u012bskomponentu kompleksiem. Piem\u0113ram, tas var mijiedarboties ar t\u0101d\u0101m viel\u0101m k\u0101 urokan\u012bnsk\u0101be. \u0160\u0101da veida mijiedarb\u012bba liecina par vara pept\u012bda l\u012bdzdal\u012bbu lok\u0101laj\u0101 vara \u0137\u012bmij\u0101, at\u0161\u0137ir\u012bb\u0101 no pla\u0161\u0101 transporta, ko nodro\u0161ina ceruloplazm\u012bns. \u0160\u0101da aktivit\u0101te var notikt noteikt\u0101s vid\u0113s, piem\u0113ram, \u0101d\u0101 vai potenci\u0101li nervu audos, kas nor\u0101da uz vair\u0101k m\u0113r\u0137tiec\u012bgu funkciju.<\/p>\n

P\u0113t\u012bjumu nol\u016bkos izmantotais vara pept\u012bds ir pieejams no t\u0101diem pieg\u0101d\u0101t\u0101jiem k\u0101 SemaxPolska. Ir svar\u012bgi uzsv\u0113rt, ka vara pept\u012bda un zin\u0101mo vara transporta sist\u0113mu attiec\u012bbas joproj\u0101m tiek p\u0113t\u012btas, un cilv\u0113kiem t\u0101s v\u0113l nav nep\u0101rprotami apstiprin\u0101tas k\u0101 fiziolo\u0123isks meh\u0101nisms.<\/p>\n

Atsauces<\/h4>\n
    \n
  • Pickart, L., Vasquez-Soltero, J. M., & Margolina, A. (2012). Cilv\u0113ka tripept\u012bds GHK-Cu oksidat\u012bv\u0101 stresa un ar noveco\u0161anos saist\u012btu de\u0123enerat\u012bvu st\u0101vok\u013cu profilaks\u0113: sekas uz kognit\u012bvo vesel\u012bbu.\u00a0Oksidat\u012bv\u0101 medic\u012bna un \u0161\u016bnu ilgm\u016b\u017e\u012bba<\/i>,\u00a02012<\/i>, 324832. https:\/\/doi.org\/10.1155\/2012\/324832 https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC3359723\/<\/span><\/li>\n
  • Mehr, A., Henneberg, F., Chari, A., G\u00f6rlich, D., & Huyton, T. (2020). Variozdevums (II)-saisto\u0161ais tripept\u012bds GHK, v\u0113rt\u012bga kristaliz\u0101cijas un f\u0101z\u0113\u0161anas atz\u012bme makromolekul\u0101rajai kristalogr\u0101fijai.\u00a0Acta crystallographica. D noda\u013ca, Struktur\u0101l\u0101 biolo\u0123ija<\/i>,\u00a076<\/i>(12. da\u013ca), 1222\u20131232. https:\/\/doi.org\/10.1107\/S2059798320013741 https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC7709198\/<\/span><\/li>\n
  • Ufnalska, I., Drew, S. C., Zhukov, I., Szutkowski, K., Wawrzyniak, U. E., Wr\u00f3blewski, W., Fr\u0105czyk, T., & Bal, W. (2021). Vid\u0113ji Cu(II)-tiod\u0101ta savienojumi Cu(II)GHK reduc\u0113\u0161an\u0101 ar glutationu: \u0113rts hel\u0101ts biolo\u0123iskai Cu(II) reduc\u0113\u0161anai.\u00a0Neorganisk\u0101 \u0137\u012bmija<\/i>,\u00a060<\/i>(23), 18048\u201318057. https:\/\/doi.org\/10.1021\/acs.inorgchem.1c02669 https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC8653159\/<\/span><\/li>\n
  • Bossak-Ahmad, K., Wi\u015bniewska, M. D., Bal, W., Drew, S. C., & Fr\u0105czyk, T. (2020). Tern\u0101rs Cu(II) komplekss ar GHK pept\u012bdu un\u00a0Cis<\/i>-Urok\u0101na sk\u0101be k\u0101 potenci\u0101ls fiziolo\u0123iski funkcion\u0101ls vara hel\u0101ts.\u00a0Starptautiskais molekul\u0101ro zin\u0101t\u0146u \u017eurn\u0101ls<\/i>,\u00a021<\/i>(17), 6190. https:\/\/doi.org\/10.3390\/ijms21176190 https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC7503498\/<\/span><\/li>\n
  • Greco, V., Lanza, V., Tomasello, B., Naletova, I., Cairns, W. R. L., Sciuto, S., & Rizzarelli, E. (2025). Vara kompleksi ar jauniem glicil-l-histidil-l-lic\u012bna-hialuronsk\u0101bes konjug\u0101tiem uzr\u0101da antioksidanta \u012bpa\u0161\u012bbas un osteog\u0113nus un angiog\u0113nus siner\u0123iskus efektus.\u00a0Biokonjug\u0101tu \u0137\u012bmija<\/i>,\u00a036<\/i>(4), 662\u2013675. https:\/\/doi.org\/10.1021\/acs.bioconjchem.4c00545 https:\/\/pubmed.ncbi.nlm.nih.gov\/40123442\/<\/span><\/li>\n
  • Hsiao, C. D., Wu, H. H., Malhotra, N., Liu, Y. C., Wu, Y. H., Lin, Y. N., Saputra, F., Santoso, F., & Chen, K. H. (2020). Rekombinantu GHK tripept\u012bdu ekspresija un att\u012br\u012b\u0161ana sp\u0113j pasarg\u0101t pret \u016bdens videi no vara iedarb\u012bbas izrais\u012btu ak\u016btu kardiotoksicit\u0101ti zebrzivti\u0146\u0101s.\u00a0Biomolekulas<\/i>,\u00a010<\/i>(9), 1202. https:\/\/doi.org\/10.3390\/biom10091202 https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC7564529\/<\/span><\/li>\n<\/ul>","protected":false},"excerpt":{"rendered":"

    Var\u0161a pept\u012bds saista vara jonus, veidojot stabilu kompleksu, kur\u0101 tas izmanto noteiktus sl\u0101pek\u013ca atomus, lai notur\u0113tu vara jonu sak\u0101rtot\u0101 un kontrol\u0113t\u0101 strukt\u016br\u0101. P\u0113t\u012bjumos\u2026<\/p>","protected":false},"author":7908,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"footnotes":""},"categories":[93],"tags":[],"class_list":["post-45614","post","type-post","status-publish","format-standard","hentry","category-kategoria-ghk-cu","beh-no-thumb"],"_links":{"self":[{"href":"https:\/\/bioevidencehub.com\/lv\/wp-json\/wp\/v2\/posts\/45614","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/bioevidencehub.com\/lv\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/bioevidencehub.com\/lv\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/bioevidencehub.com\/lv\/wp-json\/wp\/v2\/users\/7908"}],"replies":[{"embeddable":true,"href":"https:\/\/bioevidencehub.com\/lv\/wp-json\/wp\/v2\/comments?post=45614"}],"version-history":[{"count":0,"href":"https:\/\/bioevidencehub.com\/lv\/wp-json\/wp\/v2\/posts\/45614\/revisions"}],"wp:attachment":[{"href":"https:\/\/bioevidencehub.com\/lv\/wp-json\/wp\/v2\/media?parent=45614"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/bioevidencehub.com\/lv\/wp-json\/wp\/v2\/categories?post=45614"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/bioevidencehub.com\/lv\/wp-json\/wp\/v2\/tags?post=45614"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}